Industrial Purity Specifications for 4,5,6,7-Tetrahydro-2,6-Benzothiazolediamine
- High-Purity Standards: Specifications typically exceed 98.0% to 99.0% purity for pharmaceutical intermediate applications.
- Technical Data: Molecular Formula C7H11N3S with a molecular weight of 169.25 g/mol and defined melting points.
- Procurement Focus: Bulk pricing stability and verified Certificates of Analysis (COA) are critical for supply chain security.
The pharmaceutical industry relies heavily on high-quality intermediates for the synthesis of active pharmaceutical ingredients (APIs), particularly in the development of dopamine agonists. 4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine serves as a critical building block in this sector. Ensuring consistent industrial purity is paramount for downstream reaction yields and regulatory compliance. As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. adheres to stringent quality control protocols to deliver material that meets the rigorous demands of modern medicinal chemistry.
Critical Physicochemical Properties
Understanding the physical characteristics of this compound is essential for process chemists handling scale-up operations. The substance typically presents as a solid ranging from white to pale brown. Stability during storage is maintained under inert gas (nitrogen or Argon) at temperatures between 2–8 °C. The following table outlines the key technical specifications required for quality assurance.
| Parameter | Specification |
|---|---|
| Chemical Name | 4,5,6,7-Tetrahydro-1,3-benzothiazole-2,6-diamine |
| CAS Number | 106006-83-1 |
| Molecular Formula | C7H11N3S |
| Molecular Weight | 169.25 g/mol |
| Melting Point | >180 °C (decomposition) |
| Boiling Point | 359.0±42.0 °C (Predicted) |
| Density | 1.313±0.06 g/cm³ (Predicted) |
| Storage Conditions | Inert gas, 2–8 °C |
Analytical Methods for Verifying Industrial-Grade Quality
Verification of quality goes beyond simple melting point analysis. Advanced chromatographic methods are required to quantify related substances and ensure the material is suitable for GMP synthesis. High-Performance Liquid Chromatography (HPLC) is the standard method for assessing purity levels, typically targeting a minimum of 98.0% to 99.0% for commercial batches. Impurities such as unreacted starting materials or side-products from the synthesis route must be controlled below specific thresholds, often less than 0.5% for individual unknown impurities.
Heavy metal content is another critical parameter, especially for intermediates destined for human therapeutic use. Standard protocols involve ICP-MS or atomic absorption spectroscopy to limit heavy metals to ppm levels compliant with ICH Q3D guidelines. Furthermore, residual solvents from the crystallization process must be analyzed via Gas Chromatography (GC) to ensure they fall within ICH Q3C limits. A comprehensive COA provided by the supplier should detail all these parameters, ensuring transparency and traceability for the buyer.
Manufacturing Process and Supply Chain Considerations
The manufacturing process for 2,6-benzothiazolediamine 4,5,6,7-tetrahydro involves precise cyclization and amination steps. Optimization of these reaction conditions is necessary to maximize yield while minimizing the formation of difficult-to-remove isomers. Process chemists must evaluate the scalability of the route, ensuring that exothermic reactions are managed safely during bulk production. Supply chain resilience is equally important; disruptions can lead to significant volatility in bulk price structures.
When evaluating potential partners, procurement managers should assess the manufacturer's capacity for consistent batch-to-b reproducibility. Market data indicates that pricing for research-grade quantities can vary significantly, but industrial-scale contracts should offer stabilized rates. For example, small-scale laboratory packs often command higher unit prices compared to multi-kilogram or drum-level procurement. Buyers seeking validated sources for the core 7-tetrahydro-benzthiazole scaffold should prioritize manufacturers with established GMP compliance and robust logistics networks.
Impact of Related Substances on Downstream Synthesis
The presence of related substances, such as 2,6-diamino-4,5,6,7-tetrahydro-benzthiazole isomers or oxidation products, can negatively impact the subsequent synthesis of final APIs like Pramipexole. Impurities may carry through subsequent reaction steps, complicating purification and reducing overall yield. Therefore, specifying 4,5,6,7-tetrahydro-2,6-benzothiazolediamine with tight impurity profiles is a strategic decision that reduces downstream processing costs.
Storage stability is also a factor; the compound should be protected from moisture and light to prevent degradation. Proper packaging, such as double-lined fiber drums or sealed aluminum bags within containers, ensures that the material arrives at the production facility in optimal condition. NINGBO INNO PHARMCHEM CO.,LTD. utilizes such packaging standards to guarantee integrity during international shipping.
Conclusion
Securing a reliable supply of 4,5,6,7-Tetrahydro-1,3-benzothiazole-2,6-diamine requires a partner who understands both the chemical nuances and the commercial realities of the pharmaceutical supply chain. By focusing on verified industrial purity, robust analytical testing, and transparent documentation, manufacturers can mitigate risk and ensure production continuity. For organizations requiring high-specification intermediates, partnering with a dedicated entity like NINGBO INNO PHARMCHEM CO.,LTD. provides the technical support and supply security necessary for successful drug development.